Johnson & Johnson (JNJ) said Monday that new data from a phase 3 study of Tremfya, or guselkumab, showed its sustained clinical and endoscopic efficacy through week 92 in adults with moderately to severely active ulcerative colitis.

The company said 72% of patients treated with Tremfya were in clinical remission, with nearly all of them staying off steroid treatment for two months or longer, and 43% achieved endoscopic remission.

Among those who improved by week 44, 84% retained that progress through week 92, Johnson & Johnson said.

The outcomes were consistent regardless of prior exposure to biologic drugs or JAK inhibitors, according to the company.

No new safety issues were identified, and the drug's risk profile remained consistent with previous findings, the company said.